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Abstract
As many as 25% of the population age 60 years and older 
may be affected by onychomycosis, a chronic infection that 
is difficult to cure. Onychomycosis can cause pain and 
soft tissue injury that can lead to infection affecting 
gait from discomfort. Current oral medications available 
for the treatment of onychomycosis are costly and can pose 
the risk of serious side effects. The purpose of this 
study was to determine if the use of Mentholatum was an 
effective and cost-efficient means to treat onychomycosis 
of the toenail in elders. The Neuman Systems Model was 
used as the theoretical framework: specifically, Neuman's 
secondary prevention interventions to support system 
stabilization. The null hypothesis of this study was 
stated as follows : There will be no effect on the 
onychomycosis of the toenails in the elderly treated with 
Mentholatum. A quasi-experimental design was used to 
compare photographs of the toenail prior to treatment and 
photographs of the toenail at completion of the treatment. 
The subjects were drawn from three nursing homes in a 
southern state. Permission was obtained from residents and
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their responsible party for participation in the study. 
The 33 subjects ranged from 65 to 96 years. The 
Mentholatum was applied twice daily by a nurse researcher 
assistant. Digital photographs of the elder's toe were 
graded by a panel of experts, three physicians and a 
podiatrist. The nail changes were graded on a 5-point 
Likert scale. The outcomes of the study revealed 90% of 
the subjects experienced some positive change in the nail 
growth, which indicated a statistical significance. 
Therefore, the null hypothesis was rejected. Because of 
the limitation in the length of the study, there was no 
determination if nail cure could be achieved.
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Onychomycosis is a fungal nail infection which is 
known to be difficult to treat and can frequently have a 
negative impact on one's quality of life (Drake, 1997). 
Although onychomycosis can be asymptomatic, if 
symptomatic, the thickened, dystrophic nails can result in 
discomfort, pain, soft tissue injury, and infection. 
Onychomycosis accounts for 60% of consultations for nail 
disorders (Havu et al., 2000). Onychomycosis is the nail 
disease most commonly encountered by clinicians (Gupta & 
Ryder, 2002). Gupta and Ryder (2002) reported 2% to 18% of 
the population is affected by onychomycosis, with higher 
prevalence in those ages 60 years and older, diabetic, or 
HIV positive.
Because of increased use of alternative approaches by 
American citizens to both treat illness and promote 
health, the President of the United States in 2000 issued 
an executive order for the formation of a commission to 
develop policy recommendations on complementary and 
alternative medicine (CAM). The White House Commission
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recognized the need for scientific research to determine 
which CAM practices were "clinically effective and cost- 
effective" (White House Commission on Complementary and 
Alternative Medicine, 2003, fl7). The purpose of this 
research was to evaluate the effectiveness of Mentholatum 
as an alternative treatment for onychomycosis of the 
toenail in the elderly.
Establishment of the Problem
Onychomycosis occurs when the nail or nail bed is 
infected by fungi or yeast. The organism enters the 
hyponychium from the surrounding skin, producing 
inflammation, which results in hyperkeratosis and 
onycholysis. The combined effects of the detachment of the 
plate from the nail bed and subungual thickening often 
produce discomfort as well as potentially serious 
complications for vulnerable adults (Rodgers & Bassler,
2001). Schein et al. (1997) reported 54% of the patients 
with onychomycosis experienced discomfort. Bending (2002) 
stated approximately one third of fungal skin infections 
are related to onychomycosis and predicted an increase of 
onychomycosis due to an aging population and a greater 
number of people who are immunocompromised.
Onychomycosis affects the quality of life of those 
who are afflicted with the disease. Guttman (2002)
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reported onychomycosis' "greatest impact on the quality of 
life were for emotions, followed by symptoms, and then 
function" (Guttman, 2002, p. Sll). Contributing factors to 
the emotional impact were concerns the disease would 
worsen, shame, frustration, and embarrassment (Guttman,
2002). This finding was supported by Schein et al. (1997), 
who reported 67% of the patients with onychomycosis 
experienced embarrassment related to the nail's appearance 
and 40% of the patients were limited in their choice of 
shoes.
The prevalence of onychomycosis varied among reports. 
Roberts (1992) estimated an incidence of 2.8% in males and 
2.6% in female patients, whereas Heikkila and Stubbs 
(1995) estimated 8.4% of the population, and Gupta et al.
(2000) reported 16.7% of patients had abnormal nails with 
8% mycologically confirmed onychomycosis. While the 
prevalence of onychomycosis varied by study, all 
researchers reported greater incidence in males.
The prevalence of onychomycosis with a co-morbidity 
was evaluated by Ramano, Massai, Asta, and Signorini
(2001) who reported a 6% dermatophyte nail infection in 
patients with diabetes mellitus, while Gupta, Konnikov, 
and MacDonald (1998) estimated one third of diabetics will 
develop onychomycosis, de Ocariz, Arenas, Ranero-Juarez, 
and Monroy-Ramos (2001) reported nail changes were present
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in 16.11% of patients with a venous leg ulcer, with 59% of 
the nail changes attributed to onychomycosis. This high 
incidence among patients with vascular disease was 
confirmed by Gupta et al. (2002) in 4 9.2% of the patients 
with vascular disease, 22.4% of the nail changes were 
onychomycosis confirmed by mycology. Further, Gupta,
Lynde, and Jain (1997) reported 27% of patients with 
psoriasis and abnormal nails had onychomycosis.
The cost for the treatment of dermatophyte toenail 
onychomycosis in the United States as reported by Gupta
(2002) is griseofulvin (Fulvicin, Grifulvin V) at a dose 
of 500 mg twice daily for 12 months at $1,072.80 with the 
additional cost of consultation, return visits, 
mycological exam, and laboratory testing (referred to as 
additional costs) of $396; itraconazole (Sporanox) at a 
dose of 200 mg a day for 12 weeks at $1,246.58 with the 
additional costs totaling $215, and terbinafine (Lamisil) 
at a dose of 250 mg a day for 12 weeks at $701.40 with the 
additional costs totaling $245. Fluconazole (Diflucan) was 
included, although it is not been approved for treatment 
of onychomycosis, at a dose of 150 mg weekly for 12 months 
at $638.04 with additional costs totaling $366. The 
patient's systemic functions should be monitored with the 
use of these drugs. For example, kidney function should be 
monitored with the use of itraconazole and griseofulvin.
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liver function should be monitored with the use of 
itraconazole and terbinafine, and itraconazole should also 
be monitored for congestive heart failure.
Because of the evidence that a significant number of 
the population may be afflicted with onychomycosis, the 
nurse practitioner should be vigilant in the examination 
of the patient's nails. While discomfort and potential 
risks of serious complications resulting from the 
infection certainly warrant treatment, the nurse 
practitioner should consider cost, drug interactions in 
patients in polypharmacy, and the difficulties of 
differential diagnosis for abnormal nails. There is no 
research into the alterative therapy of Mentholatum as a 
treatment for onychomycosis. If effective, Mentholatum 
ointment will be able to reduce discomfort, which will 
positively impact the quality of life and do so at a cost 
less than traditional medication.
Significance to Nursing
The nurse practitioner approaches the whole person 
when providing care. With the increased use of CAM, the 
nurse practitioner must be aware of what CAMs are and 
their effects. If the client utilizes CAM, the nurse 
practitioner should be able to give knowledgeable 
information regarding safety and efficacy and aid the
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client in health care decision making. A supporting and 
accepting atmosphere should be provided, so that the nurse 
practitioner and the client can explore if and how CAM and 
traditional medicine could be blended. It is essential 
that the practitioner does not dismiss CAM as irrelevant 
or noncontributory to the health of the client. Such a 
dismissal could result in the nurse practitioner reducing 
the effectiveness of treatment and the willingness of the 
client to seek treatment from that provider. Research 
concerning the efficacy of the alternative treatment of 
onychomycosis with Mentholatum ointment will provide the 
practitioner with information to aid clients in 
determining their choice of treatment.
Theoretical Framework
The Neuman Systems Model has been selected for the 
theoretical framework of this research. The Neuman Systems 
Model has its foundations in Gestalt's theory of an 
organism maintaining homeostasis, Bernard Marx's 
philosophy of the parts are determined by the whole,
Pierre de Chardin's philosophy of life's wholeness,
Caplan's conceptual model of levels of prevention, and Han 
Seyle's definition of stress. Additionally, Betty Neuman 
utilized her own philosophies and experience to develop 
the model (Tomey & Alligood, 2002).
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A wholistic approach for client care is utilized, in 
which the client's continuous adjustment to maintain 
stability with the environment is assessed and 
interventions are planned. Neuman identified five 
variables in man which interact with the environment: 
psychological, sociocultural, physiological, 
developmental, and spiritual. When stressors, either 
interpersonal or extrapersonal, are introduced, disharmony 
of the system's parts may develop and illness ensues.
These stressors must penetrate the system's lines of 
defense. The normal life of defense is maintained by the 
client and is utilized to resist deviations from wellness. 
The flexible line of defense is the client's ability to 
rapidly adjust to stressors to maintain wellness. The 
lines of resistance are those resources used to defend 
against stressors (Neuman, 1982).
The model also includes three levels of intervention 
for a systematic approach, once stressors are suspected or 
have been identified. The first level, primary prevention, 
is implemented to support the client's flexible line of 
defense so that stability may be maintained. As related to 
this study, the client would need education regarding 
proper shoe fit and nail and skin care of the foot. The 
second level is secondary prevention. Once symptoms of 
stress have developed, the client's lines of resistance
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need strengthening to stabilize the system and reduce the 
response to the stressors. This study introduced an 
intervention for onychomycosis, which if effective, is 
less costly than the currently available traditional 
treatments. The final level, tertiary prevention, is 
implemented after either level one or level two, or both, 
have been resolved and interventions are then implemented 
to prevent recurrence. Effectively treated onychomycosis 
would be followed by continued education regarding proper 
foot care and continued monitoring for relapse. The client 
and the nurse practitioner working collaboratively may be 
at any and all of the levels at the same time in the 
treatment and education of the client (Neuman, 1982).
This study was concerned with secondary prevention.
In clients with onychomycosis, lines of resistance have 
been interrupted and disharmony has occurred. Determining 
the effects of Mentholatum on onychomycosis can provide 
information that impacts the lines of resistance and 
system stability.
Assumptions
This study was based on the following premises:
1. Onychomycosis can be accurately diagnosed without 
verification of mycology.
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2. Onychomycosis is a painful soft tissue condition 
that is expensive to treat.
3. The condition of onychomycosis is a disharmony of 
the individual lines of resistance.
Purpose of the Study
The purpose of this study was to determine if the use 
of Mentholatum is an effective and cost-efficient means to 
treat onychomycosis of the toenails in elders.
Statement of the Problem
Onychomycosis can be the cause of pain, soft tissue 
injury, and infection and can have an effect on gait due 
to discomfort. The results from the use of Mentholatum in 
treating onychomycosis is unknown. A review of the 
literature has revealed no research on this treatment.
Also, there are cost implications when compared to mouth 
prescriptive medications.
Research Hypothesis
The null hypothesis was stated as follows: There is 




For the purpose of this research, certain terms 
required definitions relating to their function within the 
study:
Mentholatum: an ointment with active ingredients of 
camphor at 4.8% and Menthol at 2.6%. The operational 
definition for this study was Mentholatum is an over-the- 
counter ointment with the active ingredients of camphor at 
4.8% and Menthol at 2.6%. The over-the-counter drug used 
was Vicks Vaporub®.
Onychomycosis: a chronic fungal or yeast infection of 
the nail bed with involvement of the nail plate. The 
operational definition for this study was onychomycosis is 
a chronic fungal condition of the toenail as diagnosed by 
the attending physician.
Elder: an adult whose age ranged from 60 to 100 
years. The operational definition of elder was an adult 
who is a resident of a nursing home and has been diagnosed 
with onychomycosis of the toenail.
Summary
Onychomycosis can affect 2% to 18% of the population, 
with a higher incidence in the elderly, diabetics, and HIV 
positive. It is a chronic disease and can be difficult to 
cure. Onychomycosis can cause soft tissue injury which can
11
lead to infection. Current oral medications are costly and 
pose risks of serious side effects. The Neuman Systems 
Model was used as the theoretical framework. The 
hypothesis of this study was that there is no effect on 
the onychomycosis of the toenails in elders treated with 
Mentholatum. The purpose of this study was to determine if 
the use - of Mentholatum ointment is an effective and cost- 
efficient means to treat onychomycosis of the toenails in 
elders.
Chapter II 
Review of the Literature
To determine the current status of research regarding 
the treatment of onychomycosis, a review of literature was 
conducted. Five research articles were reviewed for this 
study. Syed, Qureshi, Ali, and Ahmed (1999) examined the 
efficacy of butenafine and 5% Melaleuca alternifolia in 
the treatment of onychomycosis. Lebwohl et al. (2001) 
examined the safety and efficacy of terbinafine as a 
treatment. Smith, Stein, Fivenson, and Atillasoy (2000) 
examined the safety of terbinafine in patients who were 
over the age of 60 years, de Ocariz et al. (2001) examined 
the frequency of onychomycosis in patients with chronic 
venous insufficiency who had cutaneous manifestations. 
Baran et al. (2000) reported on the effects of treating 
onychomycosis with a combination therapy of amorolfine 5% 
solution nail lacquer and oral terbinafine with 
terbinafine alone.
Syed et al. (1999) studied the efficacy and 
to1erability of 2% butenafine and 5% Melaleuca 
alternifolia stated in a topical cream as a treatment for
12
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onychomycosis. Syed et al. (1999) stated that 30% of all 
mycotic infections are the chronic disease of 
onychomycosis. Onychomycosis is both difficult to diagnose 
and treat because the parasitic infection can build an 
effective barrier to the penetration of antimycotic agents 
when located in dead keratinized tissue, such as the 
toenail. Butenafine was defined as an antimycotic 
fungicidal, a "pheno-substituted benzylamine derivative"
(p. 285). The other active agent of the cream, Melaleuca 
alterni folia f was defined as an essential oil which 
contained "terpinen 4-ol, cheole and viridiflorene" (p.
285). Onychomycosis was defined as the clinical diagnosis 
of at least a 25% involvement of one of the great toenails 
by a fungal infection, which was confirmed by a positive 
culture. Clinical success was defined as 100% remission or 
a 90% to 99% improvement in the treated toenail. 
Mycological cure was defined as a negative fungal culture, 
utilizing a wet potassium hydroxide (30%) test.
Syed et al. (1999) used a randomized, double-blind, 
placebo-controlled study. The population for the study was 
obtained by referrals from medical officers or registered 
medical practitioners. The officers and practitioners had 
been informed by the researchers that pregnant and 
lactating women were not candidates for enrollment in the 
study. The sample was obtained by a baseline screening
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process which excluded subjects by specified criteria.
These criteria included:
Onychomycosis caused by molds, bacteria or Candida 
spp., a history of psoriasis, any serous concurrent 
disease, hypersensitivity to Melaleuca alternifolia 
oil, azole or benzylamine derivatives and concomitant 
therapy with drugs appearing to affect the 
bioavailability of benzylamine . . . patients who had
received systemic antifungal treatment within the 
previous three months or who were using topical 
treatment the two weeks preceding the study were not 
enrolled, (p. 285)
The sample (N = 60) included 31 males and 29 females. 
Their ages ranged from 18 years to 80 years, with a mean 
of 29.6 years. In the sample group, 48.3% were diagnosed 
with onychomycosis less than one year, and 51.7% had been 
diagnosed for one to 3 years. Thirteen subjects had used 
systemic medication longer than one year prior to the 
study, and 12 subjects had used topical treatment in the 6 
months preceding the study.
The researchers followed the Helsinki declaration 
recommendations for informed consent. All 60 subjects gave 
consent for treatment. The subjects were then randomly 
assigned to either the treatment group or the control 
group. Randomization was affected by the subject receiving 
a precoded tube of cream. The active tube would contain 
both agents, while the placebo would contain only the 5% 
Melaleuca alternifolia. There were 40 active tubes and 20 
placebo tubes. The study protocol limited active treatment
15
to 8 weeks. The groups were comparable statistically for 
the area of toenail infected as well as age and race. The 
subjects were instructed by the researchers in the three 
times a day application of the cream and application of an 
occlusive dressing. All subjects were determined to be 
compliant with the treatment and were included in the 
efficacy analysis.
The efficacy, tolerability of the cream, and overall 
success of the treatment were determined by weekly 
examination. Also, laboratory cultures obtained at weeks 
8, 24, and 36 were included in the evaluation. Upon 
examination, a determination was made if the toenail was 
ready for debridement. Debridement was done with a nail 
clipper. At 4 weeks, 4 males and 5 females had treated 
nails which were debrided; at 5 weeks, 9 males and 4 
females' treated nails were debrided. Seven males and 3 
females were debrided after 6 weeks.
At the end of the study, the code was broken, and 
Syed et al. (1999) discovered that all 32 of the debrided 
nails were from the active group. The researchers utilized 
the Cochran-Mantel-Haenszel test to compare the "clinical 
effectiveness and overall success of treatment" (p. 285) 
between the active and placebo groups. To determine if 
there was homogeneous between treatment and cure, the 
researchers used the Breslow-Day test. To compare the
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relationship between treatment and outcome, the 
researchers used the Fisher's two-tailed test. Causative 
dermatophytes were determined by laboratory culture. In 
this study. Trichophyton ruhrum was isolated in 93.3% of 
the subjects. Trichophyton tonsurans in 5%, and 
Trichophyton memtagrophytes in 1.7% of the subjects.
In the active group, 4 subjects reported mild 
inflammation. The inflammation was not severe enough to 
interrupt treatment. The result was that 93.3% of the 
subjects experienced no side effects.
At 36 weeks, an overall cure rate for the active 
group was 80%, while the placebo group's overall cure rate 
was negligible (p < .0001). Reported relapses in the 
active group after one year was negligible.
The researchers concluded that this treatment, when 
compared with systemic antimycotic treatment, was 
"significantly better" (p. 286). Syed et al. (1999) cited 
the result of an 80% cure rate, only 6.7% of the subjects 
reported mild side effects, and zero relapse, while 
systemic treatments were "accompanied by precarious drug 
related side effects and required long-term regimes to 
achieve resolution" (p. 286). Syed et al. found that 
Melaleuca alternifolia alone "did not show the expected 
response" (p. 286). The researchers did not indicate what 
response they had expected. The researchers suggested that
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the application of the placebo treatment for only 8 weeks 
was "insufficient to render its full potency" (p. 285).
Syed et al. (1999) concluded that the findings of the 
study were that the topical application of 2% butenafine 
and 5% Melaleuca alternifolia in cream, along with 
debridement, was "safe, tolerable and significantly more 
effective than placebo to cure toenail onchycomosis" (p.
286) .
Syed et al.'s study is germane to this researcher 
because it provided insights into some of the components 
used to identify a population with a disease process 
determination of the sample subjects and tests utilized to 
compare and analyze the findings of the two treatment 
groups. This researcher questions the term placebo when 
there was an expected response in its application. In this 
researcher's study, patients were similarly excluded if 
there was a diagnosis of psoriasis, had received a 
systemic antifungal treatment in the 3 months prior to 
beginning the study, or had received a topical antifungal 
treatment in the 2 weeks prior to beginning the study.
In another study Lebwohl et al. (2001) stated that 
the usual cause of onychomycosis is dermatophytes. There 
may also be nondermatophytes present. Nondermatophytes 
role in onychomycosis is unclear and a "subject of debate 
among mycologists" (p. 359). The purpose of this study was
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to determine terbinafine's efficacy in treating 
onychomycosis associated with a combination of 
dermatophyte and nondermatophyte or nondermatophyte alone. 
The primary efficacy variable was defined by Lebwohl et 
al. (2001) as effective treatment. The efficacy variables 
were defined as unaffected nail length and nail 
involvement at baseline. The secondary variable was 
defined as no nail involvement at 48 weeks and negative 
mycology. Terbinafine was defined as a "synthetic 
antifungal agent of the allylamine class" (p. 359). 
Effective treatment was defined as a specimen with both a 
negative culture and KOH microscopy and a minimum of 5 mm 
growth of unaffected nail to no nail involvement. Complete 
cure was defined as negative mycology along with no nail 
involvement. Isolated nondermatophytes were identified as 
Alternaria, Aspergillus, and Candida. The isolated 
dermatophyte was "usually" Trichophyton rubrum (p. 358).
Lebwohl et al. (2001) used a randomized, multicenter, 
double-blind, placebo-controlled study. The sample (N =
97) was randomized to the eight study centers. There were 
32 subjects in the placebo group and 65 subjects in the 
treatment groups.
The subjects were both male and female. The ages 
ranged from 18 to 70 years. The three subject groups 
received either terbinafine 250 mg once a day for 24
19
weeks, terbinafine 250 mg once a day for 12 weeks, then 
placebo for 12 weeks or placebo for 24 weeks.
Evaluation of the target toenails was done before 
treatment was initiated, then at 12, 18, and 24 weeks
during treatment. Subjects were evaluated every 6 weeks 
after treatment was completed up to week 48. Nails were 
evaluated for estimated percentage of involved nail, 
unaffected length of nail, and nail growth. Subjects and 
investigators rated the overall effectiveness of 
treatment.
In approximately 70% of the subjects, a mixture of 
dermatophytes and nondermatophytes was isolated from the 
target nail. In the remaining subjects, nondermatophytes 
alone were isolated. Candida was isolated in 33% of the 
sample, 9% in the placebo group, and 23% in the treatment 
groups. In 3 of the 9 subjects of the placebo group and 3 
of the 23 in the treatment groups Candida albicans were 
identified specifically.
Lebwohl et al. (2001) based end-of-the-study results 
on the "last post-baseline nonmissing observations up to 
and including week ninety six" (p. 359). If relapse was 
detected between weeks 48 and 96, the subjects were no 
longer included in the positive category. Adverse events 
were reported as similar between the placebo group and the 
treatment groups, with 69.2% of the treatment group
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experiencing adverse events versus 65.2% of the placebo 
group. Gastrointestinal complaints of "dyspepsia, 
abdominal pain, and flatulence" were more common in the 
treatment group. In the treatment group 2 0% of the 
subjects reported incidents of gastrointestinal symptoms 
versus 12.5% of the placebo group subjects. Reversible 
taste abnormalities were also more common for the 
treatment groups than for the placebo group.
At the end of the study, Lebwohl et al. (2001) 
identified effective treatment for all isolates in the 12- 
week treatment group to be 67.7% (21 of 31 subjects), for
the 24-week treatment group 63.6% (21 of 33 subjects), and
for the treatment groups pooled 65.6%. Complete cure for 
all isolates in the 12-week treatment group was 38.7% (12
of 31 subjects), for the 24-week treatment group 39.4% (13 
of 33 subjects), and for the treatment groups pooled 
39.1%. Negative mycology for all isolates in the 24-week 
treatment group was 74.2% (24 of 31 subjects), for the 24-
week treatment group 72.7% (24 of 33 subjects), and for
the treatment groups pooled 73.4%.
End-of-the-study results for the 12 subjects who were 
in the 12-week treatment group who cultured positive for 
Candida specifically were as follows: 83.3% negative 
mycology (10 of 12 subjects), 83.3% effective treatment 
(10 of 12 subjects), and 33.3% complete cure (4 of 12
21
subjects). The results for the 11 subjects who were in the 
24-week treatment group and who cultured positive for 
Candida specifically were 100% negative mycology (11 of 11 
subjects), 81.8% effective treatment (9 of 11 subjects), 
and 54.5% complete cure (6 of 11 subjects).
End-of-the-study results for the 3 subjects who were 
in the 12-week treatment group and who cultured positive 
for Alternaria specifically were 100% negative mycology (3 
of 3 subjects), 66.7% effective treatment (2 of 3 
subjects), and 33.3% complete cure (1 of 3 subjects). The 
results for the 5 subjects who were in the 24-week 
treatment group who cultured positive for Alternaria 
specifically were 40% negative mycology (2 of 5 subjects), 
20% effective treatment (1 of 5 subjects), and none with a 
complete cure.
End-of-the-stay study for the 2 subjects who were in 
the 12-week treatment group who cultured positive for 
Aspergillus specifically were 100% negative mycology (2 of 
2 subjects), 100% effective treatment (2 of 2 subjects),
and 50% complete cure (1 of 2 subjects). The results for 
the 5 subjects who were in the 24-week treatment group who 
cultured positive for Aspergillus specifically were 60% 
negative mycology (3 of 5 subjects), 40% effective
treatment (2 of 5 subjects), and 40% complete cure (2 of 5 
subj ects) .
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In the end-of-study results for the placebo group, 9 
subjects cultured Candida^ 6 subjects cultured Alternaria, 
and 4 subjects cultured Aspergillus. There were 7 subjects 
who had negative mycology at the end of the study. There 
were no subjects for the effective or complete cure 
results.
Lebwohl et al. (2001) concluded that receiving 
terbinafine for 24 weeks was no more effective than a 12- 
week course. They also concluded that both regimens were 
tolerated well and were safe. The isolation of 
nondermatophytes, other than Candida ̂ Alternaria ̂ and 
Aspergillus, was insufficient to allow conclusions to the 
efficacy of terbinafine regarding those organisms. Lebwohl 
et al. (2001) concluded that treatment of onychomycosis, 
in which the nondermatophyte species {Candida ̂ Alternaria, 
and Aspergillus) were specifically isolated was similar to 
both nondermatophytes and dermatophytes. Lebwohl et al. 
(2001) stated further clarification was needed for the 
"spectrum of activity and in vivo efficacy of terbinafine" 
(p. 360).
The study reviewed was germane to this researcher 
because it provided insight into the efficacy and safety 
of terbinafine. If the use of Mentholatum on onychomycosis 
shows some efficacy of treatment, then there is the 
potential for comparison of efficacy, costs, safety, and
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adverse events between terbinafine and Mentholatum in the 
treatment of onychomycosis.
Smith et al. (2000) studied the safety and efficacy 
of terbinafine as treatment for onychomycosis of the 
toenails in patients older than 60 years. These 
researchers stated onychomycosis of the toenail is a 
common disease. The prevalence of onychomycosis may be 2% 
to 8% of the population and even higher for elderly 
patients.
Smith et al. (2000) used an open-label, multicentered 
prospective study to evaluate the safety and efficacy of 
terbinafine as a treatment. Criteria for inclusion in this 
study included ". . . age 60 years or older, a diagnosis
of onychomycosis confirmed by positive potassium hydroxide 
(KOH) preparation at baseline, and toenails capable of 
regrowth" (p. 859). Any patient who had received systemic 
antifungal therapy 3 months prior to the initiation of the 
study or who had received topical antifungal therapy one 
week prior to the initiation of the study were excluded. 
Also, any patient with a diagnosis of psoriasis was 
immunosuppressed or immunodeficient, had at baseline serum 
hepatic enzyme values greater than 1.5 times normal upper 
limits, or any toenail abnormalities which interfered with 
normal toenail appearance were excluded.
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At the conclusion of baseline evaluations, those 
patients who were eligible were given a 12-week supply of 
terbinafine 250 mg to be self-administered on a once-a-day 
dose schedule. Follow-up evaluations were conducted at 6, 
12, 24, 36, 48, and 72 weeks.
Safety was assessed at baseline by physical 
examination and laboratory evaluations of hematology, 
blood chemistry, and urinalysis. At weeks 6 and 12, safety 
and tolerance were assessed by physical examination and a 
repeat of the laboratory evaluations. All follow-up visits 
included assessment of the extent of target toenail 
involved and "global assessments of therapeutic efficacy" 
(p. 860) as well as reporting of any adverse event
experienced by the participant.
The sample (N = 30) evaluated for safety included 22 
males and 8 females, ages 61 years to 84 years, with a 
mean of 67.6 years. The sample population was Caucasian. 
The duration of current episode of onychomycosis was 24 
months to 552 months, with a mean of 210.4 months.
The sample evaluated for efficacy included 13 males 
and 2 females. Their ages ranged from 61 years to 7 9 
years, with a mean of 66.8 years. All of the sample 
population were Caucasian. The mean duration of the 
current episode was 186.4 months, with a range of 24 
months to 552 months.
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For both samples, over half of the population had 
been treated previously for onychomycosis. Prior treatment 
therapies included systemic and topical antifungal 
therapies and nail avulsion.
Patient compliance was defined as at least 80% use of 
the terbinafine. This use was assessed by tablet counts at 
weeks 6 and 12. The mean compliance to the safety 
population was 98.5% at 6 weeks and 98.0% at 12 weeks.
Mean compliance was not given for the efficacy population.
No study participants in the safety group withdrew 
because of adverse events. Twenty-nine participants 
(96.7%) completed the course of antifungal treatment, and 
27 participants (90%) completed follow-up through week 27. 
No serious adverse events or deaths were reported during 
the period of study. Mild or moderate adverse events 
reported during the treatment period were transient. 
Investigators "attributed a possible, probable, or 
definite causal relationship between an adverse event and 
the study drug in 13 patients" (p. 860). Of the 13 
patients, there were 18 reported adverse events. These 
events included gastrointestinal system disorders, skin 
disorders, respiratory disorders, and central and 
peripheral nervous system disorders. Although reported in 
other studies of terbinafine, there were no reports of 
taste or ocular disturbances in this study.
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Twenty-eight participants (93.3%) received 
concomitant medication during the treatment. The 
medications were both prescription and over-the-counter. 
The most common prescription medications were 
cardiovascular agents. The prescription medications 
included ACE inhibitors, beta blockers, calcium channel 
blockers, diuretics, benzothiazepine derivatives, 
estrogen, organic nitrates, thyroid hormones, and 
sulfonamides. The over-the-counter medications included 
acetaminophen, aspirin, NSAIDS, expectorants, and vitamin 
and mineral supplements.
Terbinafine is "metabolized by at least seven 
isoenzymes of the P-450 system" (p. 863). Of the 30 
participants, 16 were concomitantly taking medications 
that were metabolized by the P-450 system. There were no 
reported interactions between these medications and the 
terbinafine.
Of the efficacy population, only one did not complete 
the study. At week 72 or the last observation, 46.7% of 
the patients experienced cure. Mycological cure did not 
fall below 92.9% after week 24. Ten of the remaining 14 
participants reported at the end of the study to be 
"satisfied or very satisfied" with the appearance of the 
target nail.
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As the increase of the elderly population continues, 
the significance of medical and quality of life issues of 
onychomycosis will continue for this population. Smith et 
al. (2000) concluded that in the presence of concomitant 
drug therapies systemic terbinafine can be used safely and 
effectively to treat onychomycosis of the toenail in the 
elderly.
Smith et al.'s (2000) study is germane to this 
researcher because it identified frequently used 
medications, both prescription and over-the-counter, 
utilized by the elderly population and the safety of 
concomitant systemic terbinafine therapy.
In the study by de Ocariz et al. (2001), the 
researchers stated that the prevalence of chronic venous 
insufficiency is high, especially in the elderly. Chronic 
venous insufficiency represents 1% to 6% of all general 
dermatological consultations. The cutaneous manifestations 
of chronic venous insufficiency may also be termed as 
venous leg ulcer or cutaneous vascular complex of the leg. 
These manifestations are divided into three grades of 
severity. Grade 1 is the presence of edema, grade 11 is 
the presence of hyperpigmentation, and grade 111 is the 
presence of an ulcer. The purpose of this study was to 
determine the frequency of nail pathology and
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onychomycosis in those patients with cutaneous 
manifestations of chronic venous insufficiency.
Onychopathy may originate because of vascular 
abnormalities such as arterial insufficiency or diabetes 
mellitus and others. The determination of the etiology of 
nail changes may be difficult due to the limited number of 
reactive patterns of the nail when affected by disease.
de Ocariz et al. (2001) used a prospective, 
observational, and transversal study. The sample {N = 36) 
consisted of patients examined by a physician at the 
dermatology department and were determined to have venous 
leg ulcers. Thirty of the participants were female 
(83.33%) and 6 participants were male (16.67%). The mean 
age of the sample population was 46.39 years. Because 
previous studies reported relationships between age and 
other systemic diseases, de Ocariz et al. excluded 
participants who were over 59 years of age or had other 
systemic diseases.
A dermatologist examined all participants, graded all 
venous ulcers, and described the nail changes. Mycological 
examinations by KOH and culture were performed on all 
patients. Functional studies were performed on 27 of the 
36 participants to classify the venous insufficiency as 
superficial or deep.
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Venous leg ulcer classification results were 10 
participants (27.77%) had grade I, 12 participants 
(33.33%) had grade II, and 14 participants (38.88%) had 
grade III. Fourteen participants were identified with 
superficial venous insufficiency; 6 of whom had grade I 
severity, 5 had grade II, and 3 had grade III. Thirteen 
participants were identified with deep venous 
insufficiency; 2 of whom had grade I severity, 3 had grade 
II severity, and 8 had grade III. While no statistically 
significant relationship was identified between the 
presence of nail changes and cutaneous disease, 
participants with deep venous insufficiency exhibited nail 
pathology more frequently.
Nail alterations were found in 22 (61.11%) of the
participants. Thirteen (59.09%) of the participants were 
identified with onychomycosis by mycologie culture or KOH. 
Fungi could not be identified in the remaining 40.91% of 
the participants. Of those participants diagnosed with 
onychomycosis, the venous leg ulcer classification was as 
follows: 3 participants (23.07%) had grade 1, 4 (30.77%)
had grade 11, and 6 (46.16%) had grade 111. Even though 
there was increased frequency of onychomycosis of the 
participants with more severe cutaneous disease, there was 
no statistically significant difference between the 
groups.
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de Ocariz et al. (2001) reported clinical features of 
nail changes to be similar for the mycotic and nonmycotic 
groups: color changes (mycotic group 100%, nonmycotic 
group 88.88%), nail plate thickening (mycotic group 
84.61%, nonmycotic group 55.55%), nail plate opacity 
(mycotic group 76.92%, nonmycotic group 44.44%), and 
subungual keratosis (mycotic group 69.23%, nonmycotic 
group 33.33%).
de Ocariz et al. (2001) concluded nail pathology was 
related more to vascular affection than to the severity of 
cutaneous affection. These researchers also identified a 
higher incidence of onychomycosis in this study population 
than had been reported in the literature for the diabetic 
or general dermatological population.
de Ocariz et al.'s (2001) study is germane to this 
research in that it provided insight into the relationship 
of nail pathology and vascular affection. The co­
morbidities of cutaneous affections and diagnosed vascular 
diseases were considered in this researcher's study.
The purpose of the study conducted by Baran et al. 
(2000) was to compare the treatment of onychomycosis with 
the combination therapy of terbinafine and amorolfine and 
terbinafine alone. Like terbinafine, amorolfine inhibits 
ergosterol production by interference of the 14-reductase
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and 7,8-isomerase stages. Baran et al. also evaluated the 
cost per cure ratios.
Baran et al. (2000) utilized a multicentre, 
randomized, prospective, open study. Inclusion criteria 
were severe dermatophyte toenail onychomycosis with matrix 
region involvement, ambulatory adult, presence of 
dermatophytes confirmed by mycology, and normal liver 
function at assessment. The subjects {N = 147) were 
randomized to one of three groups. Group 1 received 
terbinafine 250 mg daily for 6 weeks and applied 5% 
amorolfine nail lacquer weekly for 15 months. Group 2 
received terbinafine 250 mg daily for 12 weeks and applied
5% amorolfine nail lacquer weekly for 15 months. Group 3,
the control group, received terbinafine 250 mg daily for 
12 weeks.
Baseline characteristics for treatment group (n = 50) 
were as follows: gender (33 males, 66%; 17 females, 34%), 
mean age of 4 6.9 years, duration of onychomycosis was 9.1 
years, and interval since last antifungal treatment was 
22.6 months. Baseline characteristics for treatment group 
2 (n = 48) were as follows : gender (21 males, 44%, 27 
females, 56%), mean age of 47.2 years, duration of 
onychomycosis was 10 years, and interval since last 
antifungal treatment was 22.1 months. Baseline
characteristics for treatment group 3 (n = 49) were as
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follows: gender (29 males, 59%; 20 females, 41%), mean age 
of 46.7 years, duration of onychomycosis was 9.7 years, 
and interval since last antifungal treatment was 26.2 
months.
Subjects were assessed by investigators at inclusion, 
6 weeks, 3 months, and every 3 months to month 18. Nail 
sampling was done at the inclusion visit and at 3 months.
A single reference laboratory was utilized for all 
mycological testing. Liver function tests were performed 
monthly while the subjects were receiving terbinafine.
Success was defined as a negative result on 
mycological testing. Cure for the combined therapy group 
was classified only if subjects were clinically and 
mycologically clear. If subjects of this group were not 
discovered to be clear, they were classified as failures. 
In the other two groups, success was defined as no 
remaining lesion on the nail or no greater than 10% of 
residual disease of the nail. Failure was defined as less 
than a 20% reduction of total diseased nail surface.
Fifty percent of group 1 subjects, 68.8% of group 2, 
and 42.9% of group 3 completed the study. The two primary 
reasons for subjects withdrawing from the study were 
adverse events and lack of clinical response. In group 1,
4 subjects withdrew for adverse events and 13 for 
inefficacy of treatment. In group 2, 4 subjects withdrew
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for adverse events and 3 for inefficacy of treatment. In 
group 3, 4 subjects withdrew for adverse events and 16 for 
inefficacy of treatment. There were no deaths related to 
treatment. The most common adverse events included 
abdominal pain, nausea, urticaria, and liver function 
modifications. The four subjects who presented with 
abnormal liver function were withdrawn from the study. In 
all three groups, the adverse events related to the 
treatment were highest during the first 6 weeks.
A comparison of cost-per-cure ratio was also 
evaluated (costs were reported in French franc [FF]): For 
group 1, effectiveness 44%, cost 1118.20 FF, and cost-per- 
cure ratio margin 196.92; for group 2, effectiveness 
72.3%, cost 1677.90 FF, cost-per-cure ratios mean 1571.55 
FF.
Baran et al. (2000) pointed out, unlike most previous 
trials, the subjects of this study were deliberately 
selected because of nail matrix involvement. "These 
infections are generally considered to be the most 
difficult to cure" (p. 1182). At the end of the 18-month
study, 75.7% of the remaining subjects had, by mycological 
testing, no remaining infection. Baran et al. (2000) 
concluded that "substantial synergy may be generated by 
the combination of terbinafine and amorolfine in the 
treatment of severe toenail onychomycosis" (p. 1178).
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Lebwohl et al. (2001) found a 12-week course of oral 
terbinafine was both safe and efficacious in the treatment 
of onychomycosis. The researchers also found terbinafine 
was well-tolerated. Smith et al. (2000) reported that
terbinafine was a safe treatment choice for patients with 
onychomycosis who were over the age of 60 and on 
concomitant drug therapy. Baran et al. (2000) reported 
that their study results indicated that the combination of 
oral terbinafine and amorolfine had substantial positive 
effects on the treatment of onychomycosis, de Ocariz et 
al. (2001) discovered nail changes to be common in 
patients' cutaneous manifestations of chronic venous 
insufficiency and that half of these patients' nail 
changes could be attributed to onychomycosis. Syed et al. 
(1999) compared efficacy of treating onychomycosis with 2% 
butenafine and 5% Melaleuca alternifolia and 5% Melaleuca 
alternifolia in a placebo. While the combination cream was 
found to be an effective and well-tolerated treatment for 
onychomycosis, Melaleuca alternifolia alone had little 
effect on the disease.
Chapter III 
The Method
The purpose of this study was to assess the effects 
of Mentholatum on onychomycosis of the toenail in elders. 
Research has confirmed that onychomycosis impacts the 
overall health and quality of life of those who are 
afflicted. The advanced practice nurse needs to be 
cognizant of the impact of onychomycosis and the 
treatments available. With the increase of the use of 
complimentary and alternative medicines, the nurse 
practitioner must become an active participant in the 
study of their effects and efficacies.
Design of the Study
The pre-post, quasi-experimental design was utilized 
to measure the effects of applying Vick's Vaporub® to 
onychomycosis of the toenails. Gillis and Jackson (2002) 
described quasi-experimental design as one which has not 
met the requirements for classical experimental design. In 
this quasi-experimental design, there was no randomization 
of subjects to a control group. Although limited in
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controls, this design was appropriate in the current study 
because it measured the effects of treatment.
Variables
The dependent variable in this study was 
onychomycosis of the toenail. The treatment variable was 
application of Vick's Varporub®. Controlled variables 
included the co-morbidities of atherosclerosis, 
arteriosclerosis, peripheral vascular disease, and 
diabetes mellitus.
Limitations
The population for this study was limited to elders 
who reside in a nursing home. The information of this 
study is applicable to the study sample and may not 
adequately represent the general population of elders. In 
addition, the therapeutic dosing of Vick's Vaporub® is 
unknown. The length of study time may not allow for 
adequate treatment time. Inconsistency in the application 
of treatment by nursing home staff may be a limiting 
factor. External validity may be strengthened by nursing 
home staff receiving identical instruction, written 
instruction for reference, and written orders.
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Setting, Population^ and Sample
The setting for this study was three nursing homes in 
a southern state. All the nursing homes are in rural 
communities and have only physician providers. The 
population included all residents of the nursing home. The 
sample consisted of those residents diagnosed with 
onychomycosis of the toenail and who, along with the 
responsible party, signed a consent form for participation 
in the study.
Methods of Data Collection
Instrumentation, The instrument used to collect a 
visual recording of treatment effects was a digital 
camera. Data were gathered using four researcher-developed 
instruments. The first was the Inter-rater Reliability 
Survey (see Appendix A) which includes two sections. The 
first section had five photographs of onychomycosis 
toenails. The second section asks for panel member's 
determination of severity of onychomycosis for each 
photograph. The second instrument was the Demographic 
Survey (see Appendix B) which also includes two sections. 
The first section has five questions requiring a response 
from the panel member. The second section is provided for 
photographic identification, including a picture and date 
for four points of treatment. The third instrument is the
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Physician Evaluation Survey (see Appendix C ) . This 
includes three questions. The first two questions require 
initial determination of onychomycosis severity and 
significant changes on initial states of the nail using 
three additional pictures. The third question is optional 
and allows for comment reflecting photographs and nail 
appearance. The fourth instrument is the treatment survey 
(see Appendix D). On this survey, the number of treatments 
given and omitted were recorded weekly.
Procedure. Following approval of the Committee on Use 
of Human Subjects in Experimentation at Mississippi 
University for Women (see Appendix E), the researcher 
contacted the administrators of the three nursing homes by 
letter (see Appendix F). The letter requested consent to 
conduct the research within the facility. After consent 
was obtained, the researcher in-serviced the nursing staff 
on the purpose of the study, method of treatment 
application, and significance of consistency of 
application (see Appendix G). Five photographs were 
evaluated by the panel to establish inter-rater 
reliability). Then those residents who were diagnosed with 
onychomycosis of the toenail by their attending physician 
were contacted by the researcher and informed of the study 
(see Appendix H). Consent was obtained for participation 
from the resident and his or her responsible party (see
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Appendix I). Photographs of the affected nail were made 
prior to beginning treatment and then orders for treatment 
were written on the resident's chart. Photographs of the 
affected nail treated were made every 4 weeks after the 
initiation of treatment until the study was completed. At 
the completion of the study, the photographs were placed 
on the Demographic Survey and the demographic information 
entered by the researcher. The panel members then 
completed the Physician Evaluation Survey. During the 
course of the treatment, medication administration records 
for each patient were reviewed for missed applications of 
treatment. Data were then submitted to a statistician for 
appropriate analysis utilizing a t test and calculation of 
statistical percentages and means. The inter-rater 
reliability was determined by utilizing correlations and 
percentages. The Demographic Survey was analyzed utilizing 
percentages and correlations of the frequency of the co­
morbidities and presence of onychomycosis.
Chapter IV 
The Findings
The purpose of this study was to determine if the use 
of Mentholatum was an effective and cost-efficient means 
to treat onychomycosis of the toenail in elders. The 
design was pre-post, quasi-experimental to address the 
null hypothesis. The hypothesis stated there would be no 
effect on the onychomycosis of the toenail. In this 
chapter the sample and analysis of the data will be 
described in relation to the hypothesis.
Description of the Sample
Purposive sampling was utilized for collection of 
data from nursing home residents. The residents were from 
three nursing homes in a small town in a southern state. 
Attending physicians identified those residents diagnosed 
with onychomycosis. The residents and their responsible 
party, who signed a consent form for participation, 
comprised the sample. Forty-one residents began the study. 
Thirty-two residents continued to participate until 
completion of the study. The final sample consisted of 32
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residents who had signed a consent form and received 
treatments for 72 days.
Demographic Data
Demographic data were collected for all participants 
in regard to age, gender, race, and co-morbidities of 
atherosclerosis, arteriosclerosis, peripheral vascular 
disease, and diabetic mellitus. All subjects {N = 32) were 
residents in one of three nursing homes. The ages ranged 
from 65 years to 96 years. The mean age was 83 years. The 
remainder of the data regarding the sample's demographics 




























Male 12 37 . 5
Female 20 62.5
Ethnic origin
African American 1 3.1




Peripheral vascular disease 10 31.2
Diabetes mellitus 17 53.1
Note. Only subjects who completed the study are reported 
= 32.
Inter-rater Reliability
Inter-rater reliability was assessed by having the 
raters-doctors independently rate the severity of five 
photographs on a 5-point Likert scale. Once these 
measurements were obtained, an intraclass correlation
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coefficient was calculated to provide an estimate of the 
reliability of observational coding. In short, an 
intraclass correlation is a reliability measurement that 
measures the extent to which all raters mean exactly the 
same thing by their rating (Sattler, 1992). The intraclass 
correlation coefficient estimate for the raters used in 
this study was .90, with a two-sided 95% confidence 
interval from .67 to .99. This is considered to be an 
acceptable level of inter-rater agreement according to 
Sattler ( 1992) .
Level of Onychomycosis Pre-treatment
In general, physician ratings indicated that the mean 
level of onychomycosis severity before the use of 
Mentholatum ointment was M  = 3.85. Based on the 5-point 
Likert scale utilized in this study, a mean of 3.85 
indicates that the average level of onychomycosis severity 
for the 32 subjects prior to the administration of 
Mentholatum ointment was judged to be moderately severe, 
while a standard deviation of .96 indicates that the 
majority of severity ratings lie within the moderate to 
severe range. The remainder of the data regarding the 
level of onychomycosis may be seen in Table 2.
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Table 2
Percentages of Subjects within each level of Pre-treatment 
Severity Index
Level of pre-treatment f̂ %
Minimal 0 0.0
Slightly Moderate 4 12.5
Moderate 8 25.0
Moderately severe 9 28 . 1
Severe 11 34 . 4
Note. Percentages were rounded to the nearest 10̂ .̂
^N = 32.
Level of Onychomycosis Post-treatment
Following the administration of Mentholatum ointment, 
the average physician rating of change for the subjects 
was M  = 2.45. Based on the 4-point Likert scale used in 
this study, a mean of 2.45 indicates that the average 
level of change after the administration of the ointment 
was judged to fall between minimal change and new nail 
growth range {SD = .59). Most of the subjects of this 
study had a moderate to severe level of onychomycosis 
before treatment and that the level of change following 
the Mentholatum ointment was deemed to be minimal to
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moderate with signs of new nail growth. Ninety percent of 
the subjects of this study did experience a change of some 
degree in the growth and appearance of the nail. The 
remainder of data regarding the level of onychomycosis 
post-treatment may be viewed in Table 3 and Figures 1 and 
2 .
Table 3
Percentages of Subjects Within Each Level of Post-Treatment 










Level f % f % f % f %
Slightly
moderate 0 0. 0 4 100.0 0 0. 0 0 0 . 0
Moderate 1 12.5 3 37 . 5 5 50.0 0 0.0
Moderately
severe 1 11.0 2 22.0 6 67 . 0 0 0.0
Severe 1 9.0 3 27.0 7 64.0 0 0.0
Note. N = 32. Percentages were rounded to the nearest 10̂ *̂ .
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Figure 2. Number of subjects in each of the pre-treatment 
change categories.
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In order to assess if those individuals who 
experienced no or minimal change were significantly 
different from those individuals who experienced moderate 
change in terms of pre-treatment onychomycosis ratings, a 
two-sample t test was conducted. This analysis revealed 
that those individuals who were rated as demonstrating new 
nail growth (n = 17, M  = 4.02) had higher levels of 
onychomycosis ratings before treatment than those 
individuals who demonstrated no change to minimal change 
{n = 15, M  = 3.43), although not to a significant degree 
(t = 1.78; a = .05 two-tail).
Summary
Ninety percent of the subjects demonstrated some 
change in the nail growth. Three subjects had no change in 
the nail growth (M = 9.37). Twelve subjects had minimal 
change in the nail growth (M = 37.5). Seventeen of the 
subjects had new nail growth (M = 53.12).
Chapter V 
The Outcomes
Onychomycosis is the most commonly encountered nail 
disease. The thickened, dystrophic nails can result in 
pain, discomfort, soft tissue injury, and infection. 
Higher prevalence of the disease, those age 60 years and 
older and in the immunocompromised, place these 
populations at greater risk if the complications of 
onchomycosis develop. The purpose of this study was to 
determine if the application of Mentholatum ointment to 
the onychomytotic toenail of elders would affect nail 
growth. With the utilization of complementary and 
alternative medicines on the rise in the United States, 
the nurse practitioner should be able to give 
knowledgeable information regarding their safety and 
efficacy. The Neuman Systems Model was the theoretical 
framework for the study. Neuman (1982) identified three 
levels of intervention for a systematic approach when 
stressors have impacted one's lines of resistance.
The researcher utilized a pre-post, quasi­
experiment a 1 design. The severity of pre-treatment
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onychomycosis was measured on a 5-point Likert scale. 
Following a course of treatment, the effect on nail growth 
was measured on a 4-point Likert scale. The null 
hypothesis stated there would be no effect on onchomycotic 
toenails in elders treated with Mentholatum ointment.
The setting for the research was three nursing homes 
in a small town in a southern state. The 32 subjects 
ranged from 65 to 96 years.
In this chapter the findings, as well as the 
conclusions reached by the researcher, will be discussed. 
The implications of the research for nursing science, the 
limitations of the study, along with recommendations for 
further research will be set forth.
Summary and Discussion of the Findings
Findings from this study, regarding the effects of 
Mentholatum on onychomycosis of the toenail, showed a 
significant change in nail growth post-treatment. Ninety 
percent of the subjects showed some nail growth change.
The sample population was residents of three nursing 
homes in a southern state. Forty-one subjects began the 
study. The reasons for subjects being withdrawn were the 
following: subject request to be withdrawn;
hospitalization, where treatments were omitted; subject 
noncompliant to treatment regimen; and deaths, which were
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unrelated to the treatment. The 32 subjects who completed 
the 72 days of treatment application comprised the final 
sample population. The mean age was 83 years. There were 
12 males and 20 females. Thirty-one of the subjects were 
Caucasian and one was African-American.
There were 4,577 total applications of the twice-a- 
day treatment for the subject population. There were 31 
missed treatments, for a mean of less than 1%. The causes 
for missed treatment were unknown.
Interrater reliability was established by having the 
raters independently rate the severity of five photographs 
of omchomycotic nails on a 5-point Likert scale. The 
intraclass correlation coefficient estimate for the raters 
used in this study was .90, with a two-sided 95% 
confidence interval from .67 to .99.
The raters, utilizing a 5-point Likert scale, 
indicated the severity of pre-treatment onychomycosis in 
the subject population. The level of onychomycosis 
severity before the use of Mentholatum ointment was judged 
to be moderately severe (M = 3.85), while a standard 
deviation of .96 indicates the majority of severity 
ratings lie within the moderate to severe range. At the 
end of the treatment course, the raters utilized a 4-point 
Likert scale. The average physician rating of change for 
the subjects was M  = 2.45 {SD = .59). The mean of 2.45
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indicates the average level fell between minimal change 
and new nail growth. A two-sample t test was conducted to 
assess if those individuals who experienced no or minimal 
change were significantly different from those individuals 
who had experienced moderate change. This analysis 
revealed that those individuals who demonstrated new nail 
growth (n = 17, M  = 4.02) had higher levels of 
onychomycosis rating before treatment than those 
individuals who demonstrated no change to minimal change 
{n = 15, M  = 3.43), although not to a significant degree 
(t = 1.78; p  = .09, a = .05). This pattern of results 
tends to indicate that those who had greater onychomycosis 
symptomatology pre-treatment tended to display more new 
nail growth than those subjects with less severe 
onychomycosis. This pattern can be interpreted as change 
is easier to detect with more severe onychomycosis.
Conclusions
Based on the findings of this study, the following 
conclusions were drawn:
1. The application of Mentholatum to onychomycosis of 
the toenail in elders positively affected the 
growth of the nail.
2. The subjects who demonstrated new nail growth had 
a higher level of onychomycosis pre-treatment,
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than those subjects who had no change to minimal 
change.
Significance for Nursing
A number of implications for nursing science were 
derived from the study. Addressed are implications for 
nursing practice, education, and research.
Practice. Findings indicated the use of complementary 
and alternative medicines can and do impact treatment 
options for the clients of nurse practitioners. In order 
to provide accurate counseling to clients about those 
treatment options, the nurse practitioner must be aware of 
current complementary and alternative medicine practices 
and their efficacy. Because nurse practitioners are 
recognized as a professional health care resource, clients 
should be able to rely on the nurse practitioner for a 
holistic approach to their care. The nurse practitioner 
can provide secondary and tertiary interventions once the 
diagnosis of onychomycosis has been made by collaborating 
with the client on the most appropriate treatment and 
establishing realistic, obtainable goals for an optimal 
state of well-being.
Education. Schools of nursing at all levels should 
include educational opportunities on complementary and 
alternative medicines. All practicing nurses could
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encounter clients who may be utilizing complementary or 
alternative medicines. The nurse must be aware of how 
complementary or alternative medicines may impact the 
client or how they may interact with conventional medical 
treatment regimens. All nurses, whether a student or 
experienced, need educational opportunities to remain up- 
to-date with current complementary and alternative 
medicines.
Research. Findings from this study indicate that the 
use of Mentholatum may have an impact on onchomycosis. 
Additional research needs to be conducted to determine to 
what degree the treatment will ultimately affect the 
disease. Further studies of the long-term use of 
Mentholatum are needed to determine the potential for cure 
of onychomycosis. This researcher also recommends study of 
younger aged populations and the response to the 
application of Mentholatum to onychomycosis of the finger 
nail.
Limitations
The design of the study imposed a number of 
limitations that constrained the conclusions drawn from 
the research. The study was limited to elders who resided 
in a nursing home, which may limit generalization to 
elders who reside outside an institutional setting. The
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inclusion of only elders in the study further limited the 
ability to generalize to other populations of different 
ages. The sample was purposive to a quasi-experimental 
design, which contributed to a weaker design than if a 
randomized experimental design was used.
Further limiting the study was the time between 
treatment onset and the conclusion of data collection. The 
length of time did not allow for completion of a toenail 
growth cycle. Therefore, no conclusion could be made 
regarding the potential for overall nail appearance to 
improve of the possibility for mycologie cure. The total 
size of the sample population limits to some degree the 
generalization of the study than a study of a large sample 
population.
Recommendations for Future Research
The researcher made the following recommendations for 
future research based on the findings from this study:
1. Replication of the study that allows data 
collection for the length of a full toenail growth 
cycle.
2. Conduction of an experimental study of elders 
outside an institutional setting.
3. Conduction of an experimental study of different 
age populations.
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4. Conduction of an experimental study of the effects 
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Instructions: Please review the severity of the onychomycosis 
of the photographs and circle the level of severity most 











































































Ü  a. Male Ü  b . Female
4. Race:_________________________
5. Co-morbidities present:
□  a. Atherosclerosis 
O  b . Arteriosclerosis
□  c. Peripheral vascular disease 
O  d . Diabetes mellitus
Photographs
#1 (Date) #2 (Date)







Date of Evaluation: 
Subject #:__________
1. Instructions: Please review the severity of the
onychomycosis of the first photograph and circle the 
level of severity most appropriate for this particular 
photograph.
#1 #2 #3 #4 #5
Minimal Slightly Moderate Moderately Severe
moderate severe
2. Instructions: Please review the subsequent photographs 
for nail changes in comparison to the first 
photograph. Answer the following only in regard to the 
final photograph.
#1 #2 #3 #4
No changes Minimal New nail Normal nail
change growth growth







1 = All treatment given
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March 3, 2003
Ms. Susan D. Cappleman 
c/o Dr. Patsy Smyth 
P. O. Box W-910 
Campus
Dear Ms. Cappleman:
I am pleased to inform you that the members of the Committee on Human Subjects in 
Experimentation have approved your proposed research provided the consent form be amended to 
add: "Failure to participate will not affect you in any way. "
I wish you much success in your research.
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VagnK. Hansen, Ph.D. 
Provost and Vice President 
for Academic Affairs
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Mr. Jim Davidson 
Dr. Patsy Smyth 
Dr. Mary Pat Curtis
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1850 CR 748 
Dumas, MS 38 625 
December 2, 2002
Jerry Green, Administrator 
Tippah County Nursing Home 
1007 City Avenue North 
Ripley, MS 38663
Dear Mr. Green,
I am a graduate student at Mississippi University for 
Women in Columbus, MS, pursuing a Master of Science in 
Nursing, specializing as a Family Nurse Practitioner. I 
expect to graduate in August 2003.
I am requesting permission to conduct a portion of my 
research on the effects of applying Mentholatum ointment 
to toenails which have been diagnosed with onychomycosis. 
Members of your nursing home's medical staff who are in 
good standing will make the diagnosis of onychomycosis and 
will be participating in the review of the effects of the 
Mentholatum. A consent form will be signed by the 
residents and the responsible party of that resident.
I am also requesting that Mentholatum be applied twice 
daily by your nursing staff. I will supply all the 
materials necessary for the application. There will be no 
cost to the participants. However, I will be unable to 
reimburse the nursing home for the time of the nursing 
staff.
I would appreciate your allowing me access to the 
residents of the nursing home. If you have any questions 
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Inservice for Nursing Home Staff
My name is Susan Cappleman. I am a registered nurse in graduate 
school at Mississippi University for Women School of Nursing. I 
am doing a study that will observe the effects of applying 
M e n t h o l a t u m  ointment, specifically Vick's Vaporub®, on the 
onychomycosis of the toenail. This is a fungal infection that 
involves the nail or nail bed. The organism enters the 
hyponychium from the surrounding skin, producing inflammation 
which results in hyperkeratosis and onycholysis. Although 
onychomycosis can be asymptomatic, if sympotomatic, the 
thickened, dystrophic nail can result in discomfort, pain, soft 
tissue injury, and infection.
I have received permission from nursing home administration to 
conduct a study in this facility. Only those patients who have 
given their consent and the consent from their responsible 
party obtained will be participating in the study.
The attending physician will be aware of those patients who 
have consented and will allow an order for the application of 
the ointment to be written. All the attending physicians of 
this facility are participating.
The ointment will be applied by you, the nursing staff, twice a 
day. You will apply one-half inch of ointment to the designated 
great toe or toes. The toe or toes will be identified on the 
order and the time of application will be the facility's usual 
b.i.d. dosing schedule.
The ointment will be supplied by me for each patient. There 
will be paper that is marked with a 2-inch measure with one- 
half inch markings to allow for accurate dispensing of the 
ointment. You will then be able to transfer the ointment from 
the paper to the great toe of the resident. Lightly massage the 
ointment onto the nail and the surrounding skin of the nail.
There is no cost to the patient. The patient may decline to 
participate in the study or change his or her mind at any time 
during the study and withdraw. His or her decision to decline 
to participate in the study or to withdraw from the study will 
in no way affect his or her care from the attending physician.
It is essential to the outcome of this study that the 
applications be consistent between all the staff who apply the 
ointment.
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Scenario for Introducing the Study 
to Residents and Their Responsible Party
My name is Susan Cappleman. I am a registered nurse in 
graduate school at Mississippi University for Women School 
of Nursing. I am doing a study that will observe the 
effects of applying Mentholatum ointment, specifically 
Vick's Vaporub®, on fungal toenails.
Your physician has diagnosed you with a fungal infection 
of your toenail. Participation in this study is absolutely 
voluntary. If you are not interested in participating, it 
will in no way affect your treatment by your physician. 
Your name will not be used in any of the results of the 
study. 1 will keep your identity confidential if you 
should choose to participate. The risk associated with 
this study is a possible skin sensitivity to the 
Mentholatum. If that should occur, the ointment will be 
stopped immediately.
If you are interested in participating, your responsible 
party will need to agree to the study as well. I will be 
happy to answer any questions you and your responsible 
party may have.
APPENDIX I
CONSENT OF RESIDENT AND RESPONSIBLE 





My name is Susan D. Cappleman. I am a registered nurse in graduate 
school at Mississippi University for Women School of Nursing. I am 
doing a study that will observe the effects of applying Mentholatum 
ointment (Vick's Vaporub®) on fungal toenails. The goal of the study 
is to gain knowledge that may help future patients.
Participation in the study is voluntary and you have the right to 
refuse to participate or you may agree to take part in the study now 
and then change your mind. You may withdraw from the study at any time 
up to the time analysis of data begins. I cannot promise that this 
treatment will benefit you. Declining to participate will in no way 
affect your care given by your physician. During the course of the 
study, you will not be able to take antifungal medications.
Photographs will be made of the toes. The photographs will be viewed 
by a group of physicians and a podiatrist to measure the effectiveness 
of the Mentholatum. All of the results of the study will be reported 
as a group, not as individuals. Your identity will be kept 
confidential from all parties except me.
The risk is possible skin sensitivity to the Mentholatum. If this 
should occur, participation in the study would stop immediately and 
would in no way affect your care. There will be no cost to you for 
participation. Your regular physician will be monitoring you 
throughout the application of the Mentholatum.
Your participation would require:
1. Carefully reading and consideration of the consent form and to 
ask any questions you have before signing the consent form.
2. Allowing Mentholatum to be applied to the toenail and surrounding 
tissue twice a day by the nursing home staff. The estimated time 
of the study is 3 months.
3. Allowing photographs of your toes to be made before treatment 
begins and each month after until the study is completed.
At the end of the study, you will be informed of the results. If you 
have any questions regarding the study, please call me at (662) 837-
1404. A copy of the consent form can be made available on request.
Your signature will indicate that you have read and understood the 
consent form, have had all your questions answered, and have decided 
to participate.
Date Participant's Signature
Date Responsible Party's Signature
Date Investigator's Signature
